Literature DB >> 17206693

Quality-of-life measurement in patients with inflammatory bowel disease receiving social support.

S Oliveira1, C Zaltman, C Elia, R Vargens, A Leal, R Barros, H Fogaça.   

Abstract

BACKGROUND: Crohn's disease and ulcerative colitis, referred to as inflammatory bowel diseases, affect mainly young adults and have an elevated morbidity and a negative effect on quality of life. This study aimed to compare the health-related quality of life between 2 randomized groups of patients with inflammatory bowel disease: (1) the supported group (SG), patients receiving social support for an 18-month period, and (2) the control group (CG), patients receiving no social support.
METHODS: Health-related quality of life was assessed at 4 moments with the Portuguese versions of the Medical Outcomes Study Short Form 36 and the Inflammatory Bowel Disease Questionnaire (IBDQ), both validated in Brazil.
RESULTS: In the SG, using analysis of variance for repeated measures complemented by the Bonferroni test positive variations were observed (1) in the Social Aspects domain, between the first and third evaluations (P = 0.044), and (2) in the Emotional Aspects domain, between the first and second and the third and fourth evaluations (P = 0.029).
CONCLUSIONS: In the sample studied, social support, measured by use of the Inflammatory Bowel Disease Questionnaire, had a positive impact on the social and emotional aspects of quality of life.

Entities:  

Mesh:

Year:  2007        PMID: 17206693     DOI: 10.1002/ibd.20071

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  8 in total

1.  Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohn's disease.

Authors:  Wolfgang Alexander Seeger; Juliane Thieringer; Philip Esters; Benjamin Allmendinger; Jürgen Stein; Hermann Schulze; Axel Dignass
Journal:  United European Gastroenterol J       Date:  2020-06-25       Impact factor: 4.623

2.  Activation and perceived expectancies: correlations with health outcomes among veterans with inflammatory bowel disease.

Authors:  Gregory W Munson; Kenneth A Wallston; Robert S Dittus; Theodore Speroff; Christianne L Roumie
Journal:  J Gen Intern Med       Date:  2009-05-15       Impact factor: 5.128

3.  Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease.

Authors:  Xia-Peng Luo; Ren Mao; Bai-Li Chen; Yun Qiu; Sheng-Hong Zhang; Yao He; Jie Chen; Zhi-Rong Zeng; Shomron Ben-Horin; Min-Hu Chen
Journal:  Patient Prefer Adherence       Date:  2016-12-22       Impact factor: 2.711

4.  Cognitive-Behavioural Therapy for Inflammatory Bowel Disease: 24-Month Data from a Randomised Controlled Trial.

Authors:  Antonina Mikocka-Walus; Peter Bampton; David Hetzel; Patrick Hughes; Adrian Esterman; Jane M Andrews
Journal:  Int J Behav Med       Date:  2017-02

Review 5.  Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties.

Authors:  Xin-Lin Chen; Liang-Huan Zhong; Yi Wen; Tian-Wen Liu; Xiao-Ying Li; Zheng-Kun Hou; Yue Hu; Chuan-Wei Mo; Feng-Bin Liu
Journal:  Health Qual Life Outcomes       Date:  2017-09-15       Impact factor: 3.186

6.  Are there also negative effects of social support? A qualitative study of patients with inflammatory bowel disease.

Authors:  Alexander Palant; Wolfgang Himmel
Journal:  BMJ Open       Date:  2019-01-21       Impact factor: 2.692

7.  An Exploratory Study of Inflammatory Bowel Disease and the Psychosocial Factors Affecting Health-Related Quality of Life.

Authors:  Nirmala Sarwan; Ricardo Jurawan; Rudrunath Singh; Vijay Kumar Chattu
Journal:  Med Sci (Basel)       Date:  2019-01-25

8.  Peer support for carers and patients with inflammatory bowel disease: a systematic review.

Authors:  Ada Adriano; Dean M Thompson; Christel McMullan; Malcolm Price; David Moore; Lesley Booth; Jonathan Mathers
Journal:  Syst Rev       Date:  2022-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.